Project Details
Project Description
Acute myeloid leukaemia (AML) has a dismal 5-year survival expectation (25%). This proposal describes a bold initiative to create an innovative trial platform to flexibly screen novel drugs and combinations for proof-of-concept activity. The International AML Platform Consortium (IAPC) trial will randomize multiple drugs in parallel versus a control arm, in patients achieving remission after chemotherapy. The IAPC will study checkpoint inhibitors targeting PD1, TIM3 or both; BET bromodomain inhibitors; and direct activation of apoptosis with venetoclax combined with low-dose cytarabine. Five parallel study arms (4 drug, 1 control, 1 waiting) will study the effect of maintenance therapy on clinical relapse and minimal
residual disease (MRD). The IAPC will be led by a team of clinician researchers who are experts in AML and the development of BCL2 inhibitors (CI Andrew Wei and Andrew Roberts), BET inhibitors (CI Mark Dawson) and immunotherapeutics (CI David Ritchie). Central to the feasibility of the IAPC trial will be the formation of a precision medicine network of laboratories to characterize the spectrum of AML mutations (CI Mark Dawson) and gene fusions (CI Paul Ekert) in each patient to inform the design of patient-centred MRD tools to track clonal patterns of response and failure with ultra-high sensitivity (CI Adam Ivey). The IAPC trial will leverage adaptive Bayesian techniques (CI John Reynolds) to replace ineffective drugs with new treatment options and graduate promising drugs for further development, complemented by research into productivity as a novel health economic endpoint. The IAPC will forge stronger links between industry partners and academic AML groups, strengthen ties between city and regional Victorian hospitals and form effective partnerships between complementary Melbourne laboratories to service the AML community. The potential outcomes from this proposal are protean, providing the VCA with a pivotal opportunity to have an enduring impact on AML research in Victoria.
residual disease (MRD). The IAPC will be led by a team of clinician researchers who are experts in AML and the development of BCL2 inhibitors (CI Andrew Wei and Andrew Roberts), BET inhibitors (CI Mark Dawson) and immunotherapeutics (CI David Ritchie). Central to the feasibility of the IAPC trial will be the formation of a precision medicine network of laboratories to characterize the spectrum of AML mutations (CI Mark Dawson) and gene fusions (CI Paul Ekert) in each patient to inform the design of patient-centred MRD tools to track clonal patterns of response and failure with ultra-high sensitivity (CI Adam Ivey). The IAPC trial will leverage adaptive Bayesian techniques (CI John Reynolds) to replace ineffective drugs with new treatment options and graduate promising drugs for further development, complemented by research into productivity as a novel health economic endpoint. The IAPC will forge stronger links between industry partners and academic AML groups, strengthen ties between city and regional Victorian hospitals and form effective partnerships between complementary Melbourne laboratories to service the AML community. The potential outcomes from this proposal are protean, providing the VCA with a pivotal opportunity to have an enduring impact on AML research in Victoria.
| Status | Finished |
|---|---|
| Effective start/end date | 13/04/17 → 12/04/22 |